9 results match your criteria: "Hungary. reusz.gyorgy@med.semmelweis-univ.hu.[Affiliation]"

How to define and assess the clinically significant causes of hematuria in childhood.

Pediatr Nephrol

August 2023

1st Department of Pediatrics, Semmelweis University, 53-54 Bókay János Street, Budapest, 1083, Hungary.

Given the wide diversity of causes of hematuria, ranging from simple urinary tract infections with rapid recovery to severe glomerulonephritis with fast decline in kidney function, it is essential to recognize the underlying disease. The first objective of the assessment is to determine whether the cause of the hematuria is medically significant. The combination of hematuria with proteinuria, the presence of hypertension, or worsening kidney function can represent signs of progressive kidney disease.

View Article and Find Full Text PDF

Background: Kidney transplantation (KTx) improves prognosis in children with kidney failure; still, these patients are prone to cardiovascular damage due to multiple risk factors. Our aim was to assess myocardial structure and function in pediatric KTx by conventional and speckle-tracking echocardiography (STE) in association with established cardiovascular risk factors.

Methods: Forty-two KTx and 39 healthy age- and gender-matched children were evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • Atypical hemolytic-uremic syndrome (aHUS) is linked to defects in the complement system, but its relationship with immune diseases like Crohn's disease (CD) and long-term treatment efficacy is not well understood.
  • A pediatric patient with aHUS and CD experienced fluctuating levels of complement inhibition during six years of treatment with eculizumab, despite stable dosing, revealing a connection between CD relapses and incomplete complement blockage.
  • Close monitoring of complement inhibition and eculizumab levels is crucial in aHUS patients with CD, as uncontrolled intestinal disease may necessitate increased doses of the medication to achieve effective treatment.
View Article and Find Full Text PDF

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-antibody. Although recent recommendations suggest using it as a primary treatment for aHUS, important questions have arisen about the necessity of immediate use of eculizumab in all cases.

View Article and Find Full Text PDF